Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP
Phase III, Randomized, Double-Blind, Study Evaluating Efficacy/Safety/Tolerability of Meropenem-Vaborbactam Compared to Piperacillin/Tazobactam in Adult Patients With Complicated Urinary Tract Infections, Including Acute Pyelonephritis
Sponsor: Department of Health and Human Services
Listed as NCT02166476, this PHASE3 trial focuses on Acute Pyelonephritis and Urinary Tract Infection Complicated and remains completed. Sponsored by Department of Health and Human Services, it has been updated 9 times since 2014, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jul 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 4 earlier versions
-
Jun 2018 — Jul 2018 [monthly]
Completed PHASE3
-
Nov 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Feb 2017 — Nov 2017 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Nov 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Department of Health and Human Services
- Melinta Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Arequipa, Peru , Athens, Greece , Augusta, United States , Baja, Hungary , Barcelona, Spain , Belo Horizonte, Brazil , Bologna, Italy , Brest, Belarus , Bucharest, Romania , Budapest, Hungary and 60 more locations